Xcout Intel
Damona Pharmaceuticals
Damona Pharmaceuticals is a biotechnology research company developing microcircuit precision medicines aimed at restoring cognitive functions across various brain disorders. The company is located in Toronto, Ontario.
Subscribe to see Damona Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Damona Pharmaceuticals at a glance
Damona Pharmaceuticals is a pharmaceuticals company headquartered in Canada. Xcout tracks 8 named people at Damona Pharmaceuticals, including John Reilly (Chief Executive Officer).
Damona Pharmaceuticals leadership
- John ReillyChief Executive Officer
- Jeff IrwinChief Financial Officer
- Rob RisingerConsulting Chief Medical Officer
- Etienne SibilleScientific Founder
- James B. SummersFormer VP, Neuroscience Research, AbbVie
- Jacki JenuthLumira Ventures
2 more named people on record for Damona Pharmaceuticals, with roles, board committees and tenure — see the full roster →
Damona Pharmaceuticals competitors
A few of Damona Pharmaceuticals's closest competitors — see the full list of competitors and alternatives →
Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company headquartered in Edmonton, Canada, specializing in the development of innovative delivery systems for genetic therapies.
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Deep Genomics is a biotechnology research company that collaborates across disciplines to solve complex molecular design challenges. The company's corporate headquarters are located in Toronto, Ontario, Canada, a hub for innovation.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Get Damona Pharmaceuticals's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Damona Pharmaceuticals in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access